公开(公告)号：US20230021834A1

公开(公告)日：2023-01-26

申请号：US17320574

申请日：2021-05-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang

IPC: A61K31/4439 ,  A61K31/40 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4468 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D207/14 ,  C07D211/58 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D491/048

Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

公开(公告)号：US12005054B2

公开(公告)日：2024-06-11

申请号：US17320574

申请日：2021-05-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang

IPC: A61K31/4439 ,  A61K31/40 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4468 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D207/14 ,  C07D211/58 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D491/048

CPC classification number: A61K31/4439 ,  A61K31/40 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4468 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D207/14 ,  C07D211/58 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D491/048

Abstract: Disclosed are compounds of Formula 1,




stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

公开(公告)号：US11045457B2

公开(公告)日：2021-06-29

申请号：US16289311

申请日：2019-02-28

Applicant: Takeda Pharmaceutical Company Limited ,  Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang

Inventor： Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang

IPC: C07D207/14 ,  A61K31/4439 ,  A61K31/40 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4468 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07D211/58 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D491/048

Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

公开(公告)号：US09475816B2

公开(公告)日：2016-10-25

申请号：US14426369

申请日：2013-09-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Mingnam Tang

IPC: C07D487/04 ,  C07D519/00 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/437 ,  A61K31/496 ,  C07D487/14 ,  A61K31/4162 ,  A61K31/506

CPC classification number: C07D487/04 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  C07D487/14 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

公开(公告)号：US20160009735A1

公开(公告)日：2016-01-14

申请号：US14860573

申请日：2015-09-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Zacharia Cheruvallath ,  Stephen L. Gwaltney ,  Andrew John Jennings ,  Mark Sabat ,  Mingnam Tang ,  Haixia Wang ,  Jeffrey A. Stafford

IPC: C07D513/04 ,  C07D403/12 ,  C07D401/12 ,  C07D417/12

CPC classification number: C07D513/04 ,  A61K31/437 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  Y02A50/473

Abstract: Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

公开(公告)号：US20150225405A1

公开(公告)日：2015-08-13

申请号：US14426369

申请日：2013-09-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Mingnam Tang

IPC: C07D487/04 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/437 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4162 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  C07D487/14 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中L，R 1，R 2，R 3，R 4，R 5，R 6和R 7在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。

公开(公告)号：US20200061041A1

公开(公告)日：2020-02-27

申请号：US16289311

申请日：2019-02-28

Applicant: Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang ,  Takeda Pharmaceutical Company Limited

Inventor： Zacharia Cheruvallath ,  Jason Green ,  Ben Johnson ,  Kristin Schleicher ,  Huikai Sun ,  Mingnam Tang

IPC: A61K31/4439 ,  C07D401/12 ,  A61K31/4545 ,  C07D403/12 ,  A61K31/506 ,  C07D401/14 ,  A61K31/40 ,  C07D207/14 ,  C07D211/58 ,  A61K31/4468 ,  A61K31/501 ,  A61K31/497 ,  A61K31/4355 ,  C07D491/048 ,  A61K31/438

Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

公开(公告)号：US09434743B2

公开(公告)日：2016-09-06

申请号：US14378305

申请日：2013-02-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Philip Erickson ,  Jun Feng ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Joanne Miura ,  Sean Murphy ,  Mingnam Tang ,  Huong-Thu Ton-Nu

IPC: C07D498/04 ,  C07D401/04 ,  C07D471/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D487/04 ,  C07D401/14 ,  C07D413/14 ,  C07D231/56 ,  C07D403/10 ,  C07D407/14 ,  C07D413/04 ,  C07D413/10 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06

CPC classification number: C07D498/04 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07D231/56 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D407/14 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

公开(公告)号：US20150005232A1

公开(公告)日：2015-01-01

申请号：US14378305

申请日：2013-02-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Zacharia Cheruvallath ,  Philip Erickson ,  Jun Feng ,  Mallareddy Komandla ,  John David Lawson ,  Christopher McBride ,  Joanne Miura ,  Sean Murphy ,  Mingnam Tang ,  Huong-Thu Ton-Nu

IPC: C07D498/04 ,  A61K31/416 ,  A61K45/06 ,  C07D401/04 ,  A61K31/4439 ,  C07D471/04 ,  A61K31/437 ,  A61K31/5383 ,  C07D403/04 ,  A61K31/506 ,  C07D405/04 ,  C07D413/10 ,  A61K31/4245 ,  C07D417/04 ,  A61K31/427 ,  C07D401/14 ,  A61K31/5377 ,  C07D487/04 ,  A61K31/53 ,  C07D231/56

CPC classification number: C07D498/04 ,  A61K31/416 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07D231/56 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D407/14 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。